Page 56 - Read Online

Page 8 of 8 Lin et al. Hepatoma Res 2018;4:26 I http://dx.doi.org/10.20517/2394-5079.2018.27

cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Cancer Res 2006;66:1664-74.
52. Reck M, von Pawel J, Nimmermann C, Groth G, Gatzemeier U. Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine
in patients with advanced non-small-cell-lung-cancer (NSCLC). Pneumologie 2004;58:845-9.
53. Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O’Dwyer PJ. Phase I trial of
tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 1997;15:773-80.
54. Cai TY, Liu XW, Zhu H, Cao J, Zhang J, Ding L, Lou JS, He QJ, Yang B. Tirapazamine sensitizes hepatocellular carcinoma cells to
topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2014;13:630-42.
55. Liu XW, Cai TY, Zhu H, Cao J, Su Y, Hu YZ, He QJ, Yang B. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor
signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy 2014;10:111-22.
56. Chang L, Liu X, Wang D, Ma J, Zhou T, Chen Y, Sheng R, Hu Y, Du Y, He Q, Yang B, Zhu H. Hypoxia-targeted drug Q6 induces G2-M
arrest and apoptosis via poisoning topoisomerase II under hypoxia. PLoS One 2015;10:e0144506.
57. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, Hideg K, Kuppusamy P. EF24 induces G2/M arrest and apoptosis
in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 2007;282:28609-18.
58. Zhao R, Tin L, Zhang Y, Wu Y, Jin Y, Jin X, Zhang F, Li X. EF24 suppresses invasion and migration of hepatocellular carcinoma cells in
vitro via inhibiting the phosphorylation of Src. Biomed Res Int 2016;2016:8569684.
59. Jeong W, Rapisarda A, Park SR, Kinders RJ, Chen A, Melillo G, Turkbey B, Steinberg SM, Choyke P, Doroshow JH, Kummar S. Pilot
trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid
tumors. Cancer Chemother Pharmacol 2014;73:343-8.
60. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O. ENMD-1198, a novel tubulin-binding agent
reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo.
BMC Cancer 2008;8:206.
61. Granowitz EV, Tonomura N, Benson RM, Katz DM, Band V, Makari-Judson GP, Osborne BA. Hyperbaric oxygen inhibits benign and
malignant human mammary epithelial cell proliferation. Anticancer Res 2005;25:3833-42.